ENDRA Life Sciences (NDRA) Expected to Announce Quarterly Earnings on Monday

ENDRA Life Sciences (NASDAQ:NDRA) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($1.23) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

ENDRA Life Sciences Stock Up 5.8%

ENDRA Life Sciences stock opened at $3.45 on Monday. ENDRA Life Sciences has a 12 month low of $2.90 and a 12 month high of $11.96. The stock has a market cap of $2.59 million, a P/E ratio of -0.13 and a beta of -0.08. The company’s fifty day simple moving average is $3.88 and its 200-day simple moving average is $4.87.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Ascendiant Capital Markets reduced their price objective on ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.